Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional chemotherapy. Volasertib (BI 6727) is a cell-cycle re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Gopalakrishnan, Bhavani, Cheney, Carolyn, Mani, Rajeswaran, Mo, Xiaokui, Bucci, Donna, Walker, Alison, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Rueter, Bjoern, Waizenegger, Irene C., Heider, Karl-Heinz, Blum, William, Vasu, Sumithira, Muthusamy, Natarajan
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839395/
https://ncbi.nlm.nih.gov/pubmed/29515764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23880
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars